GENE ONLINE|News &
NewLimit Raises $435 Million to Fund First Human Clinical Trial for Liver Therapeutic
Longevity startup NewLimit secured $435 million in new funding to support the development of its first clinical trial, which will focus on a liver-targeted therapeutic. The company intends to use the capital to advance this medicine through the initial stages of human testing.
The financing round provides the necessary resources for NewLimit to transition its research from the laboratory to clinical application. While the company specializes in longevity-focused biotechnology, this specific trial marks its first move into testing a treatment in human subjects. The company has not yet released a specific timeline for the commencement of the trial or the details regarding the drug’s mechanism of action.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: June 2, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
ArcelorMittal, thyssenkrupp, and voestalpine Call for EU Emissions Trading System Reforms to Protect Steel Competitiveness
2026-06-18
Six Taipei Biotechs Head to BIO 2026 in San Diego, With Precision Medicine, Drug Delivery, and Bioprocess Innovation in Focus
2026-06-18
2026 Tang Prize in Biopharmaceutical Science Honors Three Pioneers of “Living Drug” Immunotherapies
2026-06-17
EVENT
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan
